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A BST R AC T   
 
Aim: To evaluate the effectiveness of contrast-induced acute kidney injury (CI-AKI) prophylaxis 
retrospectively, using calcium channel blockers (CCB) before and after contrast exposure and 
comparing them with patients using angiotensin converting enzyme inhibitors (ACEI), which has not 
been explored by many studies. 
Methods: The study was performed in Afyon Kocatepe University, Faculty of Medicine Research 
Hospital, Cardiology Department between January 2014 and June 2016. Eighty patients using 
dihydropyridine (amlodipine 10 mg), non-dihydropyridine (diltiazem 60 mg) CCB or ACEI in the 
form of monotherapy before coronary angiography were included.  
Results: In the CCB and ACEI group, CI-AKI development rates were 15.7% (n=8) and 24.1% (n=7), 
respectively (p = 0.383; Fisher's exact test). When the CCB group was evaluated as dihydropyridine 
and non-dihydropyridine subsets, CI-AKI development rates were found to be similar as well (p = 
0.445; Fisher’s exact test) in each subset.  
Conclusion: In our study, we evaluated one of today's important dilemma; the methods related to the 
prophylaxis of CI-AKI. Our study shows that there is no difference in the development of CI-AKI 
between patients using the calcium channel blocker group drugs and ACEI as monotherapy. However, 
in our study, the mean age of patients using CCB was significantly higher than the group using ACEI.  
 Keywords: Contrast-induced acute kidney injury, calcium channel blockers, angiotensin converting 
enzyme inhibitors, renoprotective effect.                                                                                   
          © 2020 experimentalbiomedicalresearch.com                                                                                                                                  
        Dr. Burçin Meryem Atak Tel 
Department of Internal Medicine, Afyon Kocatepe 
University, Faculty of Medicine, Afyon, Turkey 
E mail: burcinatak@hotmail.com     
Received: 2020-04-19 / Revisions: 2020-04-28 
Accepted: 2020-05-06 / Publication Date: 2020-06-13 
 
Introduction 
Contrast media (CM) has a plethora of 
applications in routine non-invasive or 
percutaneous invasive imaging examinations 
and therapeutic interventions. Unfortunately, 
the use of CM is associated with a number of 
complications, the most serious being contrast-
induced acute kidney injury (CI-AKI) [1].  
A general definition of CI-AKI is an 
impairment in renal function occurring within 3 
days following the intravascular administration 
of CM and the absence of an alternative 
etiology [2]. Contrast media administration has 
been said to be the third leading cause of 
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hospital-acquired acute renal failure in the past 
3 decades [3]. Chronic kidney disease, 
dehydration, diabetes mellitus (DM), advanced 
age, increased volume of CM and recurrent 
administrations are well-known risk factors of 
CI-AKI [4]. 
In spite of the vast clinical importance of CI-
AKI, its understanding and the 
pathophysiology behind CI-AKI is not fully 
explained [2, 3]. Most reviews show a complex 
pathophysiology overlaying medullary 
ischemia and hypoxia, oxidant damage, 
intratubular obstruction, hypertonicity, plasma 
viscosity and many pathways including 
endothelins, nitric oxide, reactive oxygen 
species, prostaglandins and adenosine [5].  
Calcium has been proposed as a mediator of the 
vasoconstrictor response to CM [6]. Also 
Intracellular Ca²⁺ overload is considered to be a 
key factor in CI-AKI [3]. The rationale is based 
on the fact that while in normal subjects, the 
Na⁺-Ca²⁺ exchanger pumps Ca²⁺ outside the 
renal tubular epithelial cells to keep 
intracellular Ca²⁺ low. Under the effect of CM, 
the Na⁺-Ca²⁺ exchanger can reversibly extrude 
Na⁺ for Ca²⁺ influx, thereby leading to 
intracellular Ca²⁺ overload, which is considered 
a key factor in ischemic cell injury and in CI-
AKI [7]. The increase in intracellular calcium 
provokes a vasoconstrictive response in 
intrarenal circulation and would been important 
mediator of epithelial cell apoptosis and 
necrosis. Thus, calcium channel blockers 
(CCB) have been hypothesized to have 
protective effects against CI-AKI [8]. The CCB 
attenuated the vasoconstrictor response of CM 
in animal studies, although prophylactic use of 
CCB has not gained wide acceptance [6]. 
Literature show opposing results; some authors 
suggesting them to be protective [9, 10], others 
finding no benefit at all [11-13]. However, 
these researches are very old and more recent 
studies are needed. In this study we compared 
patients who used dihydropyridine (amlodipine 
10 mg), nondihydropyridine (diltiazem 60 mg) 
CCB and ACEI; and underwent coronary 
angiography. We compared serum creatinine, 
blood urea nitrogen (BUN), urea levels and 
glomerular filtration rates (GFR) before and 3-
15 days after the coronary angiography. We 
planned to examine the changes in the GFR 
values by taking demographic data into 
consideration. 
 
Materials and methods 
We used a definition of CI-AKI which is widely 
accepted; impairment in renal function 
occurring within 3 days following the 
intravascular administration of CM and the 
absence of an alternative etiology [2].  
The study included 80 patients using 
dihydropyridine, non-dihydropyridine CCB 
and ACEI from 4027 patients who underwent 
coronary angiography in the Cardiology 
department of Afyon Kocatepe University, 
Faculty of Medicine, Research Hospital 
between January 2014 and June 2016. 
Information about patients was obtained by 
retrospectively examining patient files. Prior to 
the study, the necessary ethics committee 
approval was obtained (Decision no; 29-5-
2016). All procedures performed in this study 
were in accordance with the ethical standards of 
the institutional and/or national research 
committee and with the 1964 Helsinki 
declaration and its later amendments or 
comparable ethical standards.  
 
Inclusion and exclusion criteria: Of the 4027 
patients; only 80 patients used dihydropyridine 
(amlodipine 10mg), nondihydropyridine 
(diltiazem 60mg) or ACEI before coronary 
angiography as monotherapy. 2635 patients 
using multidrug therapies were excluded. Also 
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1074 patients were excluded because they were 
not using CCB or ACEI.  
Individuals under the age of 18 and over 85 
were not included in the study (total of 84 
patients). Data was obtained by retrospectively 
scanning patient files. Patients were included in 
the study if the registration data were sufficient. 
Patients were excluded if serum creatinine, 
BUN, urea levels and GFR value within 3 to 15 
days of coronary angiography were not in the 
database. Also patients with missing 
demographic data were excluded. 154 patients 
were excluded because of a missing data in their 
files. 
 
Statistical Analysis 
The data of the patients’ who are included in the 
study has been collected and submitted in a 
database for the study. These variables include; 
age, gender, smoking habits, body mass index 
(BMI), hypertension duration (in years), 
systolic and diastolic blood pressure 
measurements, comorbid disease, patients 
laboratory findings (before and after contrast 
exposure) including hemogram, BUN, serum 
creatinine, urea, glomerular filtration rate 
(GFR), lipid analysis, and electrolytes. Data 
was analyzed using IBM SPSS 18.0. 
Descriptive statistical results of the study data 
were expressed as arithmetic mean ± standard 
deviation. While evaluating the groups, patient 
distributions were given as frequencies. The 
data obtained were evaluated primarily with 
descriptive statistics. The suitability of the data 
to the parametric conditions was evaluated with 
the Kolmogorov-Smirnov test. Mann-Whitney 
U test was used for the quantitative evaluation 
between the CCB and ACEI groups. Wilcoxon 
Test was used to compare the median values of 
the two dependent groups, and the Chi Square 
test was used to compare the categorical data 
and the groups. In the results obtained from the 
statistical tests applied, it was considered 
significant when a 95% confidence interval (CI) 
and the p-value below 0.05. 
 
Results  
When the demographic data of the patients 
included in the study were evaluated, 55 
(68.8%) were male and 25 (31.2%) were 
female. There were 29 (56%) men, 22 (44%) 
women in the patient group using calcium 
channel blocker; and 26 (89%) men and 3 
(11%) women in the ACEI group. There was a 
significant difference in gender distribution 
between the two groups (p = 0.002). The mean 
age of the patients was 60.4 ± 12.5. When 
analyzed as CCB and ACEI groups, the average 
age of patients using CCB was 62.6 ± 12.6, and 
the average age of the patient group using ACEI 
was 56.5 ± 11.5.The mean ages of the two 
groups were found to be statistically different 
(p = 0.01). BMI was similar between the CCB 
group and the ACEI group (p = 0.222).When 
systolic blood pressures of patients were 
evaluated, mean systolic blood pressure was 
132.9 ± 15.3 (range: 110-180) mmHg in the 
CCB group and 119.1 ± 10.6 (range: 86-140) 
mmHg in the group using ACEI. Systolic blood 
pressure was significantly higher in the CCB 
group than the ACEI group (p <0.001). Again, 
when groups using CCB and ACEI were 
compared, diastolic blood pressures were 
similar (p = 0.663). The duration of involved 
drug use in both groups was similar (p <0.233). 
Of the 80 patients who are enrolled in the study, 
25 had no other comorbid disease. 31 (38, 8%) 
had DM, 5 (6.3%) had a history of 
cerebrovascular disease, 7 (8.8%) had 
congestive heart failure, 3 (3.8%) had 
peripheral arterial disease, 15 (18.8%) had 
hyperlipidemia, 10 (12.5%) had chronic lung 
disease. Disease distributions were similar in 
CCB and ACEI groups (p> 0.5). 
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When the drugs used by patients were 
classified, 21 people were using 
nondihydropyridine (diltiazem 60mg), 30 
people were using dihydropyridine  
(amlodipine 10 mg) and 29 people were using 
ACEI. 
When staged according to the JNC8 report, only 
10 of the 80 patients were found to have optimal 
systolic and diastolic blood pressure. Despite 
the use of CCB, blood pressure levels of 5 
patients were found to be stage-2 hypertension. 
It was found that patients using trandolapril had 
more effective control over blood pressure 
compared to patients using CCB. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The laboratory values of the two groups are 
presented in Table 1. When the laboratory 
values of the two groups were compared, the 
hemoglobin, hematocrit, platelet, fasting blood 
glucose, uric acid, calcium (Ca), AST, ALT, 
lipid panel (LDL, VLDL, HDL, total 
cholesterol, triglyceride) values were also 
similar between the CCB group and the ACEI 
group. There was a significant difference 
between phosphorus and HbA1c levels between 
the two groups. Serum phosphorus level in the 
CCB group was 2.6-4.5 (mean 3.51 ± 0.5) mg / 
dl, and in the group using ACEI 1.5-4.2 (mean 
3.1 ± 0.6) mg/dl (p = 0.043). The HbA1c level 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Laboratory 
Parameters 
CCB Group ACEI Group 
p-value 
Min-max Mean Min-max Mean 
Hb(g/dl)     9- 17 12.7±2.0 9,6-17,0 13.07±2.1 0.538 
Htc (%)     28-57 40.3±6.5 29-50 40.6±6.1 0.641 
Plt (x10³) 66-369 232.3±64.3 177-352 239.4±55 0.944 
FBG (mg/dl)    60-377 142.6±65,9 74-358 158.5±76.5 0.597 
Uric Acid (mg/dl)   2,8-27 5.8±3.5 2.8-12 5.6±2 0.768 
Ca⁺⁺ (mg/dl)   7,9-10 9.1±8.7 7,8-10 9.1±0.5 0.864 
Phosphorus (mg/dl)    2,6-4,5 3.51±0.5 1,5-4,2 3.1±0.6 0.043 
K⁺ (mEq/l) 3,1-5,5 4.4±0.5 3,2-5,1 4.4±0.4 0.028 
HbA1c % 5,3-12 7.8±1.8 9,0-13,0 10.4±1.6 0.017 
AST (U/L)      13-78 26.7±12.5 12-206 40.4±38.7 0.222 
ALT (U/L)   5-167 28.8±31.4 8-61 22.8±12.08 0.980 
LDL (mg/dl)  25-228 114.2±46.3 51-212 108.5±40.9 0.572 
VLDL (mg/dl)     9-106 31.8±17.5 9-63 29.2±14.2 0.663 
HDL (mg/dl)  14-68 37.7±12.4 16-61 36.4±10.1 0.676 
Total 
cholesterol(mg/dl) 120-324 168.1±58.8 84-284 161.1±48.6 0.420 
Triglyceride(mg/dl) 85-531 151.4±94.0 48-316 147.5±72.3 0.890 
 
Table 1. Comparison of laboratory parameters of two groups. 
 
CCB: calcium channel blockers, ACEI: angiotensin converting enzyme inhibitors Hb: Hemoglobin, Htc: hematocrit, Plt: 
Platelet, FBG: fasting blood glucose. 
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was 5.3-12% (mean: 7.8 ± 1.8) in the CCB 
group and 9-13% (10.4 ± 1.6) in the group using 
ACEI (p = 0.017). Serum potassium level was 
4.2 ± 0.5 mEq/dl in the CCB group, and 4.4 ± 
0.4 mEq/dl in the ACEI group. There was a 
significant difference between the potassium 
levels of two groups (p = 0.02).  
Pre-contrast exposure serum creatinine, BUN, 
urea and GFR were similar (p values = 0.359, 
0.904, 0.707, 0.426, respectively). The mean 
urea of the group using CCB after contrast 
exposure was 43.1 ± 23.0 mg/dl, and 38.9 ± 
23.6 mg/dl in the ACEI group (p = 0.08). Cr 
value of CCB group was 1.06 ± 1.4 mg/dl, and 
1.0 ± 0.4 mg/dl in the ACEI group (p = 0.11). 
After contrast exposure, GFR was calculated as 
85.9±27.9 (ml/min/1.73m2) for the CCB group 
and 88.9±33.9 (ml/min/1.73m2) for the ACEI 
group. When the two groups were compared in 
terms of GFR levels after contrast exposure, 
they were found similar (p = 0.818). 
In the CCB and ACEI groups, CI-AKI 
development rates were 15.7% (n=8) and 
24.1% (n= 7), respectively. The two groups 
were similar in terms of CI-AKI development 
rates (p = 0.383; Fisher’s exact test).  
When the CCB group was evaluated as 
dihydropyridine and nondihydropyridine 
groups, the rates of CI-AKI were similar (p = 
0.445; Fisher’s exact test). 
 
Discussion 
CI-AKI has become an important problem as a 
result of the increased use of contrast today. 
Again, it increases the life-threatening 
complications such as sepsis, bleeding, and 
respiratory failure, and increases the hospital 
stay and leads to an increase in medical costs. 
Prevention and treatment of such an important 
complication is very essential for the physician, 
patient and the country's economy. The data 
obtained up to this day confirms the idea that 
the volume expansion method is the most 
important method for reducing the risk of CI-
AKI [14]. But the pathophysiology behind CI-
AKI is not fully explained [2, 3]. Therefore 
search for a prophylaxis of CI-AKI still 
continues.  
Intracellular Ca²⁺ overload is an important 
factor in ischemic cell injury and considered to 
be a key factor in CI-AKI pathophysiology [3]. 
Therefore CCB, which could prevent 
intracellular Ca²⁺ overload, have been 
suggested as a protective measure to prevent 
CI-AKI [7]. However previous data shows 
conflicting results. Most of the animal studies 
on rats showed promising results. Yu-Yan Fan 
et al., Aritomi et al. and Duan et al. all showed 
similar renoprotective effects of CCB [15-17]. 
Beyazal et al. [14] compared isotonic sodium 
chloride infusion alone, 5% dextrose solution 
with sodium bicarbonate infusion and isotonic 
sodium chloride infusion plus 3 days of CCB 
therapy (one day before and two days after the 
contrast exposure) for CI-AKI prophylaxis. 
They find no significant difference between 
groups.  
Arici et al. [18] also find no significant 
difference in a prospective study with patients 
pretreated with amlodipine; a dihydropyridine 
CCB; than placebo. Whereas Russo et al. [10] 
reported that CCB nifedipine may prevent AKI 
induced by hyperosmolar contrast agent. 
Neumayer et al. [9] investigated a total of 35 
patients after intravascular administration of 
contrast media to determine the effects on renal 
function of a 3-day treatment with the CCB 
nitrendipine (n=16), compared the findings in a 
placebo-treated control group (n=19). 
Prophylactic use of nitrendipine preserved the 
glomerular filtration rate, whereas control 
patients showed a significant (27%) reduction 
in GFR two days after contrast-media injection 
(p≤0.01).As a result, it was emphasized that 
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nitrendipine, a nondihydropyridine CCB, could 
decrease the risk of CI-AKI [9]. 
In our study we compared two groups, who 
were using ACEI and CCB as monotherapy; 
and found no significant difference in 
development of CI-AKI. But this can be an 
effect of ACEI as well as CCB. ACEI also have 
been used to prevent CI-AKI in the past. Gupta 
et al. conducted a study of 71 patients who 
underwent coronary angiography and 
concluded that ACEI is effective against CI-
AKI compared to placebo [19]. But more recent 
studies find no beneficial effect of ACEI. 
Furthermore Toprak et al. reported that in a 
randomized controlled study of 80 patients 
included; five patients (8.3%) in the ACEI 
group and 1 patient (3%) in control group 
developed CI-AKI and this difference was 
statistically significant (p=0.02). They 
concluded that using ACEI is a risk factor for 
development of CI-AKI [20]. In our study, 8 
(15.7%) patients in CCB group and 7 (24.1%) 
patients in ACEI group developed CI-AKI. The 
two groups were similar in terms of CI-AKI 
development rates statistically (p = 0.383). This 
may be the result of both drugs lowering the 
risk factor of CI-AKI equally.  
Age is a direct risk factor of developing CI-
AKI. Especially elderly patients older than 70-
75 years are at risk of developing CI-AKI [7]. 
Hui et al. showed in their study that amlodipine, 
a CCB, may decrease the risk of developing 
CMN in elderly patients [21]. In our study, the 
mean age of the CCB group was significantly 
higher than the ACEI group. The mean age of 
the patients in CCB group was 62.6 ± 12.6, 
against the mean age of the patients in ACEI 
group was 56.5 ± 11.5 (p = 0.01). This could 
mean that CCB reduced the risk of older 
patients in the CCB group to a younger age risk 
level. Therefore two groups statistically appear 
indifferent in CI-AKI development rates. 
Oguzhan et al. compared hydration therapy 
alone, versus valsartan-amlodipine 
combination plus hydration treatment in 
patients who have stage-II chronic kidney 
disease and going through coronary 
angiography. CI-AKI rates was 17.8% (n=8) in 
the CCB/ARB plus hydration group and 6.7% 
(n=3) in the only hydration group. As a result, 
they showed that amlodipine and valsartan 
treatment did not decrease the risk of CI-AKI 
[22]. Davidson et al. prospectively examined 
1144 patients undergoing cardiac 
catheterization. They showed that the risk of 
developing CI-AKI does not decrease in 
patients using various CCB drugs [23]. In their 
prospective randomized study, Arıcı et al. [18] 
divided the 29 patients into two groups of 
amlodipine (n=15) and placebo (n= 14). Only 
one patient developed CI-AKI in each group. 
Two groups were similar statistically regarding 
CI-AKI development rates (amlodipine group: 
6.6% n=1; placebo group: 7.1% n=1). Although 
our study was designed retrospectively, it is 
important to show similar results and rates with 
these three prospective studies. 
The main limitations of our study are 
retrospective study design and relatively small 
sample size. Also; age difference between two 
groups and the fact that we could not randomize 
groups for contrast dose and their hydration 
status is a limitation of our study. 
 
Conclusion 
In our study, we evaluated one of today's 
important dilemma; the methods related to the 
prophylaxis of CI-AKI. Our study shows that 
there is no difference in the development of CI-
AKI between patients using the CCB and ACEI 
as monotherapy. However, in our study, the 
mean age of patients using CCB was 
significantly higher than the group using ACEI. 
The volume expansion method is the most 
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favorable method for reducing the risk of CI-
AKI and the pathophysiology behind CI-AKI is 
not fully explained. Therefore we need more 
studies exploring CI-AKI prophylaxis. 
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